Products
Ralzapastotug Biosimilar Monoclonal Antibody (TIGIT) for Research
Cat No.: GMP-Bios-INN-1355
Anti-TIGIT/WUCAM/VSTM3 therapeutic antibody (Pre-made Ralzapastotug biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Ralzapastotug (development code AB-308) is a humanized monoclonal antibody targeting TIGIT. It is developed by Arcus Biosciences for Multiple myeloma, non-Hodgkin's lymphoma, Non-small cell lung cancer et al. in Phase I development.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1355-1mg | 1mg | 3090 |
| GMP-Bios-INN-1355-10mg | 10mg | |
| GMP-Bios-INN-1355-100mg | 100mg | |
| GMP-Bios-INN-1355-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Ralzapastotug biosimilar, Whole mAb, Anti-TIGIT/WUCAM/VSTM3 Antibody: Anti-TIGIT/T-cell immunoreceptor with Ig and ITIM domains/V-set and immunoglobulin domain-containing protein 9/V-set and transmembrane domain-containing protein 3 therapeutic antibody |
| INN Name | Ralzapastotug |
| Target | TIGIT/WUCAM/VSTM3 |
| Format | Whole mAb |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1+2+3 Isotype | G1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-I |
| Est. Status | Discontinued |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2022 |
| Year Recommended | 2023 |
| Companies | Arcus Biosciences |
| Conditions Approved | na |
| Conditions Active | na |
| Conditions Discontinued | Multiple myeloma;non-Hodgkin's lymphoma;Non-small cell lung cancer;Melanoma;Solid tumours |
| Production | na |
| Development Tech | na |
